Intra-tumoural Microbiota Remodels the Tumour Immune
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA838603 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR19226083_1.fastq.gz | Fastqsanger.gz | |||
| SRR19226083_2.fastq.gz | Fastqsanger.gz | |||
| SRR19226084_1.fastq.gz | Fastqsanger.gz | |||
| SRR19226084_2.fastq.gz | Fastqsanger.gz | |||
| SRR19226085_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 24 |
Similar Datasets
Project description:Esophageal squamous cell carcinoma (ESCC) accounts for ~90% of all cases of esophageal cancer and the sixth most common cause of cancer related death worldwide. 1, 2 It remains a globally challenging disease and mostly diagnosed cases requires a multidisciplinary approach with extensive treatments including surgery, chemoradiotherapy and/or chemotherapy. ESCC has a relatively high tumor mutational burden,3 suggesting that it could benefit from PD-1 blockade. Recently, three phase III clinical trials reported that PD-1 blockade significantly improved progression-free survival (PFS) and overall survival (OS) when combined with chemotherapy as first-line therapy in advanced/metastatic ESCC.4, 5 Moreover, in 2021 ASCO annual meeting, two phase II clinical trials reported that neoadjuvant chemo-immunotherapy (NACI) induced an obvious improvement of the pathologic complete response (pCR) for resectable ESCC (35. 3% and 42.5%, respectively). Several phase III trials on this topic are ongoing (NCT04807673, NCT04848753, NCT04280822) (https://clinicaltrial s.gov/ct2/show/NCT04807673), indicating that neoadjuvant NACI would become promising treatment for locally advanced ESCC. Nevertheless, not all ESCC patients could respond to NACI. Patients who responded well or poorly to neoadjuvant immunotherapy were treated with surgery. We collected samples from these patients and conducted single-cell sequencing to analyze the tumor immune microenvironment of patients with different therapeutic effects, compare the differences in immune cell composition in the immune microenvironment, and explore more effective neoadjuvant therapy methods.
2023-07-07 | GSE203115 | GEO
Project description:Gene expression microarray profiling on glioblastoma intra-tumour regions, where the study hypothesis states that the infiltrative tumour margin harbours a distinct transcriptomic profile from all non-infiltrative tumour regions. Data is from three patients (patient 9, 14 and 15) where regions 1-4 per patient were obtained from non-infiltrative intra-tumour regions, and region 5 was obtained from the infiltrative margin. All patients underwent craniotomy with intra-operative image guidance and visualization of 5ALA induced fluorescence to obtain infiltrative margin biopsies.
2024-11-30 | E-MTAB-14600 | biostudies-arrayexpress
Project description:Intra-tumour heterogeneity in lymphoid malignancies encompasses selection of genetic events and epigenetic regulation of transcriptional programs. Clonal-related neoplastic cell populations are unsteadily subjected to immune editing and metabolic adaptations within different tissue microenvironments. How tissue-specific mesenchymal cells impact on the diversification of aggressive lymphoma clones is still unknown. We investigated the intra-tumour heterogeneity and the specific mesenchymal modifications that are associated with A20 diffuse large B-cell lymphoma (DLBCL) cells seeding of different tissue microenvironments. We found that the tissue microenvironment casts a relevant influence over A20 transcriptional landscape also impacting on Myc and DNA damage response programs. Extending the investigation to mice deficient for the matricellular protein SPARC, a stromal prognostic factor in human DLBCL, we demonstrated a different immune imprint on A20 cells according to stromal Sparc proficiency.
2020-11-02 | GSE157920 | GEO
Project description:High Humidity Remodels Gut Microbiota
| PRJEB36876 | ENA
Project description:High Humidity Remodels Gut Microbiota
| PRJEB36877 | ENA
Project description:High Humidity Remodels Gut Microbiota
| PRJEB36879 | ENA
Project description:<p>Gliotoxin is a secondary metabolite produced by Aspergillus fumigatus, known to play a significant role in immune regulation and virulence phenotypes. This study investigates how the deletion of gliotoxin biosynthesis remodels the metabolic state of A. fumigatus and subsequently affects host immune responses. We employed a multi-omics approach, integrating fungal metabolomics and host transcriptomics data, to assess the impact of gliotoxin deletion on intra- and extracellular metabolic processes. The results showed that the loss of gliotoxin biosynthesis significantly altered the metabolic profile of A. fumigatus, with distinct changes observed in metabolites from both fungal mycelia and culture supernatants. These metabolic alterations were closely linked to changes in host cellular immune-related pathways. Notably, in macrophages and epithelial cells, treatment with gliotoxin led to significant changes in immune gene expression, revealing its role in modulating host immune responses.</p><p>Furthermore, treating macrophages with gliotoxin inhibited the secretion of inflammatory cytokines and reduced the cells' phagocytic capacity for A. fumigatus conidia, indicating that gliotoxin may play a role in suppressing host defense mechanisms. However, transcriptomic analysis also suggested that exposure to gliotoxin could promote the expression of certain immune genes, pointing to a complex interaction between the fungal metabolite and the host immune system. Through integrative analysis, we identified key metabolic and immune pathways affected by gliotoxin. These findings provide new insights into the impact of gliotoxin deletion on fungal virulence and host immunity, and offer a theoretical basis for potential therapeutic strategies in managing Aspergillus fumigatus infections.</p>
2026-05-11 | MTBLS14012 | MetaboLights
Project description:<p>Gliotoxin is a secondary metabolite produced by Aspergillus fumigatus, known to play a significant role in immune regulation and virulence phenotypes. This study investigates how the deletion of gliotoxin biosynthesis remodels the metabolic state of A. fumigatus and subsequently affects host immune responses. We employed a multi-omics approach, integrating fungal metabolomics and host transcriptomics data, to assess the impact of gliotoxin deletion on intra- and extracellular metabolic processes. The results showed that the loss of gliotoxin biosynthesis significantly altered the metabolic profile of A. fumigatus, with distinct changes observed in metabolites from both fungal mycelia and culture supernatants. These metabolic alterations were closely linked to changes in host cellular immune-related pathways. Notably, in macrophages and epithelial cells, treatment with gliotoxin led to significant changes in immune gene expression, revealing its role in modulating host immune responses.</p><p>Furthermore, treating macrophages with gliotoxin inhibited the secretion of inflammatory cytokines and reduced the cells' phagocytic capacity for A. fumigatus conidia, indicating that gliotoxin may play a role in suppressing host defense mechanisms. However, transcriptomic analysis also suggested that exposure to gliotoxin could promote the expression of certain immune genes, pointing to a complex interaction between the fungal metabolite and the host immune system. Through integrative analysis, we identified key metabolic and immune pathways affected by gliotoxin. These findings provide new insights into the impact of gliotoxin deletion on fungal virulence and host immunity, and offer a theoretical basis for potential therapeutic strategies in managing Aspergillus fumigatus infections.</p>
2026-05-11 | MTBLS14011 | MetaboLights
Project description:Development of a vaccine formula that alters the tumour-infiltrating lymphocytes to be more immune active against a tumour is key to the improvement of clinical responses to immunotherapy. Here, we demonstrate that, in conjunction with E7 antigen specific immunotherapy, and IL-10 and PD-1 blockade, intra-tumoral administration of caerin 1.1 and 1.9 peptides further improves the tumour microenvironment (TME) when compared with injection of a control peptide. We used single cell transcriptomics and mass spectrometry-based proteomics to quantify changes in cellular activity across different cell types within the TME. We show that the injection of caerin 1.1/1.9 increases immune activating macrophages and NK cells, while reducing immunosuppressive macrophages with M2 phenotype, and increased numbers of activated CD8+ T cells with higher populations of memory and effector-memory CD8+ T subsets. Proteomic profiling demonstrated activation of Stat1 modulated apoptosis and production of nitric oxide. Further, computational integration of the proteome with the single cell transcriptome was consistent with deactivation of immune suppressive B cell function following caerin 1.1 and 1.9 treatment.
2021-08-18 | PXD021264 | Pride
Project description:Intra-tumoral heterogeneity in melanoma arises from dynamic cancer cell plasticity and underlies various mechanisms of immune escape. Here, we combined high-plex immunofluorescence imaging with spatially resolved transcriptomics to map the architecture of melanoma cell states and their interactions with the immune microenvironment in primary cutaneous tumours prior to adjuvant anti-PD1 immune checkpoint inhibitor (ICI) treatment. Computational analyses showed that melanoma cells organise into spatially restricted patches, with a preferential organisation of undifferentiated cells associated with poor ICI efficacy. Neighbouring immune cell composition varied according to cancer cell states, with a crucial involvement of specific subsets of tumour-associated macrophages, driven by signalling pathways involving tumour-derived and microenvironmental cues such as IFN-γ and hypoxia. Integrated spatial analyses further revealed tumour-immune ecosystems that stratify patient outcomes, delineating configurations either associated with ICI efficacy or metastatic relapse. These results uncover the spatial landscape of tumour ecosystems and identify signalling pathways as potential targets for improving the efficacy of ICI in melanoma.
2026-06-23 | GSE300446 | GEO